Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 8

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 8
---
 respect to each of Proposals 2, 3 and 4, only “FOR” and “AGAINST” votes will be counted for purposes of determining the votes received in connection with each proposal. Broker non-votes and abstentions will have no effect on determining the outcome of a proposal except to the extent that broker non-votes and abstentions results in the number of affirmative votes with respect to such proposal being less than the required quorum.

Am I entitled to dissenters’ rights or appraisal rights?

No. Our shareholders are not entitled to dissenters’ rights or appraisal rights on any matter being submitted to shareholders at the Meeting.

How can I find out the voting results?

We expect to announce preliminary voting results at the Meeting. Final voting results will be published in a Current Report on Form 8-K to be filed with the SEC within four business days after the Meeting.

<div align='center'>-5-</div>

BOARD OF DIRECTORS Set forth below are the names, ages, tenure, and certain biographical information of each of our directors nominated for election at the Meeting. Such information is as of April 18, 2025. For personal reasons, one of our current directors, Mr. Bailey, requested that our Nominating and Corporate Governance Committee consider not nominating him for reelection at the Meeting, and our Nominating and Corporate Governance Committee did not nominate him for reelection. His term on our Board will end at the Meeting.

| Name                  |     | Age |     | Director Since |
| Michael H. Mulroy     |     |  59 |     | October 2014   |
| Dipti Amin            |     |  61 |     | April 2021     |
| Deborah Andrews       |     |  67 |     | April 2014     |
| Neal C. Bradsher, CFA |     |  59 |     | July 2009      |
| Brian M. Culley       |     |  53 |     | September 2018 |
| Anula Jayasuriya      |     |  68 |     | May 2021       |
| Angus C. Russell      |     |  69 |     | December 2014  |

Michael H. Mulroy . Mr. Mulroy was appointed Chairman of the Board in April 2024. Mr. Mulroy served as the Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc. (AST)